Eli Lilly: Direct Attack on Johnson & Johnson in the Market for Depression Therapies
Reading Time: 3 minutes
Eli Lilly diversifies its business model beyond weight loss and diabetes medications with an aggressive acquisition strategy. The acquisition of AtaiBeckley secures BPL-003 as a novel therapy for the treatment of treatment-resistant depression. Mounjaro and Zepbound serve as key growth drivers, increasing overall revenue by 56% in Q1. The stock is trading at an all-time high. Eli Lilly (LLY) is one of the world's leading pharmaceutical companies with a market capitalization of over $1.1 trillion, developing and marketing prescription...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
